TriSalus Life Sciences, Inc.
TLSITriSalus Life Sciences, Inc. in brief
TriSalus Life Sciences, Inc. is a listed company in the Healthcare sector, based in Westminster, Colorado, USA. Its market value was $234 M on 28 October 2026, which makes it the 15,689th largest listed company in the world and the 3,060th largest in the USA on this site. In the year to December 2025 it had sales of $45 M and a net loss of $39 M. It employs about 102 people and Mary T. Szela is its chief executive. Its shares trade under the symbol TLSI (Nasdaq).
Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.
About TriSalus Life Sciences, Inc.
We are a growing, oncology focused medical technology business seeking to transform outcomes for patients with solid tumors by integrating our innovative delivery technology with standard-of-care therapies, and with our investigational immunotherapeutic, nelitolimod, a class C Toll-like receptor 9 agonist, for a range of different therapeutic and technology applications. Our ultimate goal is to transform the treatment paradigm for patients battling solid tumors. We have developed an innovative technology designed to overcome two of the most significant challenges that prevent optimal delivery and performance of therapeutics in these difficult-to-treat diseases: (i) high intratumoral pressure caused by tumor growth and collapsed vasculature restricting the delivery of oncology therapeutics and (ii) off target delivery. Nelitolimod, specifically, combined with our technology aims to address the immunosuppressive properties of tumor immune cells in liver, pancreas and other solid tumors. By systematically addressing these barriers, we aim to improve response to therapies and to enable improved patient outcomes.
From the company's annual report filed with the US SEC: read the report
TriSalus Life Sciences, Inc. timeline
- 2020
- •· approximateFirst filing with the US SECThe company's first electronic filing in SEC EDGAR.
- 🔔Initial public offering as MedTech Acquisition CorporationFinal prospectus filed with the SEC on 21 December 2020; shares registered for exchange trading on 16 December 2020. The blank-check company later merged with the business that carries the name today.
- 2023
- ✎Renamed TriSalus Life Sciences, Inc.Formerly MedTech Acquisition Corporation.
- 2025
- 💰Record revenue of $45 millionFY2025, the highest of the 4 years on record.
Events of TriSalus Life Sciences, Inc. from SEC EDGAR and the company's financial years. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.
Market cap history
World rank over time
Rank in USA: #3,981 (Jul 2023) · #3,176 (Jan 2024) · #1,659 (Mar 2026) · #2,811 (Aug 2026) · #2,994 (Oct 2026) · #3,064 (Oct 2026)
Key ratios
- P/E ratio (TTM)
- n/m (loss)
- Price / sales (TTM)
- 5.1×
- Price / book
- —
- Free cash flow yield
- -8.1%
- Net margin (TTM)
- -56.6%
- Operating margin
- -59.7%
- Return on equity
- —
- Liabilities / assets
- 195.8%
- Net debt
- $13M
- Revenue growth
- +53.4%
- R&D / revenue
- 33.1%
- Revenue per employee
- $443 K
- Profit per employee
- $-385 K
Financial history
| Fiscal year ending | Revenue | Growth | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $45M | +53.4% | $-27M | $-39M | -86.9% |
| Dec 2024 | $29M | +59.0% | $-36M | $-30M | -102.1% |
| Dec 2023 | $19M | +49.3% | $-54M | $-59M | -320.7% |
| Dec 2022 | $12M | — | $-36M | $-47M | -380.6% |
| Dec 2021 | — | — | $-3M | $5M | — |
Cash flow, debt and per share
| Fiscal year ending | Operating cash flow | Capital spending | Free cash flow | EPS (diluted) | Dividend / share |
|---|---|---|---|---|---|
| Dec 2025 | $-18M | $1M | $-19M | $-1.84 | — |
| Dec 2024 | $-41M | $0M | $-41M | $-1.31 | — |
| Dec 2023 | $-51M | $1M | $-51M | $-6.77 | — |
| Dec 2022 | $-32M | $1M | $-33M | $-161.55 | — |
| Dec 2021 | $-2M | — | — | — | — |
Quarterly results
Latest quarter to Sep 2026: revenue $13M (+11.3% on a year earlier), net income $-9M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Sep 2026.
SEC filings
- Nov 10, 202610-QQuarterly report · period to Sep 2026
- Nov 10, 20268-KCurrent reportResults of operations
- Sep 22, 20268-KCurrent reportOther events
- Aug 6, 202610-QQuarterly report · period to Jun 2026
- Aug 6, 20268-KCurrent reportResults of operations
- May 14, 20268-KCurrent reportShareholder vote
- May 12, 202610-QQuarterly report · period to Mar 2026
- May 12, 20268-KCurrent reportResults of operations
- Apr 29, 20268-KCurrent reportDirectors or officers changed
- Apr 7, 20268-KCurrent reportDirectors or officers changed · Regulation FD disclosure
- Mar 31, 2026DEF 14AProxy statement
- Mar 5, 202610-KAnnual report · period to Dec 2025
Official filings of TriSalus Life Sciences, Inc. with the US Securities and Exchange Commission.
Annual results
- Revenue
- $45 M
- Operating income
- $-27 M
- Net income
- $-39 M
For year ending December-2025 · source: SEC filing
Balance sheet
- Total assets
- $35 M
- Total liabilities
- $69 M
- Total equity
- $-34 M
As of December-2025
Top 82 institutional investors in TriSalus Life Sciences, Inc.#
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 1 | First Light Asset Management, LLC | 7,416,274 | +863,783 (+13.18%) | 12.02% | $32 M | Nov 16, 2026 |
| 2 | BlackRock, Inc. | 2,611,150 | -48,068 (-1.81%) | 4.23% | $11 M | Nov 13, 2026 |
| 3 | Vanguard Capital Management LLC | 1,720,671 | -8,714 (-0.50%) | 2.79% | $7 M | Nov 13, 2026 |
| 4 | Cerity Partners LLC | 1,605,414 | +1,876 (+0.12%) | 2.60% | $7 M | Nov 13, 2026 |
| 5 | Geode Capital Management, LLC | 1,123,372 | -66,695 (-5.60%) | 1.82% | $5 M | Nov 6, 2026 |
| 6 | Gilder Gagnon Howe & Co LLC | 818,936 | -31,145 (-3.66%) | 1.33% | $4 M | Nov 16, 2026 |
| 7 | State Street Corp | 668,897 | +57,934 (+9.48%) | 1.08% | $3 M | Nov 12, 2026 |
| 8 | Kennedy Capital Management LLC | 625,690 | +149,429 (+31.38%) | 1.01% | $3 M | Nov 13, 2026 |
| 9 | Thompson Siegel & Walmsley LLC | 529,534 | -7,000 (-1.30%) | 0.86% | $2 M | Nov 5, 2026 |
| 10 | Nantahala Capital Management, LLC | 500,000 | -1,500,000 (-75.00%) | 0.81% | $2 M | Nov 13, 2026 |
| 11 | White Pine Capital LLC | 497,186 | -50,391 (-9.20%) | 0.81% | $2 M | Nov 9, 2026 |
| 12 | Morgan Stanley | 418,014 | +16,200 (+4.03%) | 0.68% | $2 M | Nov 13, 2026 |
| 13 | Northern Trust Corp | 351,899 | -27,673 (-7.29%) | 0.57% | $2 M | Nov 16, 2026 |
| 14 | Invesco Ltd. | 351,753 | +295,379 (+523.96%) | 0.57% | $2 M | Nov 12, 2026 |
| 15 | Vanguard Portfolio Management LLC | 308,945 | -20,519 (-6.23%) | 0.50% | $1 M | Nov 13, 2026 |
| 16 | Vanguard Fiduciary Trust Co | 306,101 | -14,855 (-4.63%) | 0.50% | $1 M | Nov 13, 2026 |
| 17 | Perkins Capital Management Inc | 297,991 | +62,890 (+26.75%) | 0.48% | $1 M | Nov 2, 2026 |
| 18 | Bank Of America Corp /de/ | 222,323 | +16,981 (+8.27%) | 0.36% | $1 M | Nov 16, 2026 |
| 19 | Royce & Associates LP | 200,060 | 0 (0.00%) | 0.32% | $1 M | Nov 9, 2026 |
| 20 | UBS Group AG | 176,920 | -46,127 (-20.68%) | 0.29% | $1 M | Nov 10, 2026 |
| 21 | Charles Schwab Investment Management Inc | 158,987 | +51,042 (+47.29%) | 0.26% | $1 M | Nov 16, 2026 |
| 22 | Goldman Sachs Group Inc | 115,354 | +32,956 (+40.00%) | 0.19% | $0 M | Nov 16, 2026 |
| 23 | AQR Capital Management LLC | 114,161 | -3,816 (-3.23%) | 0.18% | $0 M | Nov 16, 2026 |
| 24 | Bank of New York Mellon Corp | 99,093 | -12,441 (-11.15%) | 0.16% | $0 M | Nov 5, 2026 |
| 25 | Corient Private Wealth LP | 95,002 | -52,150 (-35.44%) | 0.15% | $0 M | Nov 16, 2026 |
Show all 82: investors 26 to 82
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 26 | CWA Asset Management Group, LLC | 72,000 | 0 (0.00%) | 0.12% | $0 M | Oct 19, 2026 |
| 27 | Bridgeway Capital Management, LLC | 68,406 | -1,094 (-1.57%) | 0.11% | $0 M | Nov 16, 2026 |
| 28 | Nuveen, LLC | 66,896 | +2,998 (+4.69%) | 0.11% | $0 M | Nov 10, 2026 |
| 29 | Empowered Funds, LLC | 63,906 | New | 0.10% | $0 M | Nov 13, 2026 |
| 30 | MSD Partners, L.P. | 39,999 | 0 (0.00%) | 0.06% | $0 M | Nov 16, 2026 |
| 31 | Price T Rowe Associates Inc /MD/ | 39,335 | 0 (0.00%) | 0.06% | $0 M | Nov 16, 2026 |
| 32 | Deutsche Bank AG\ | 38,623 | -9,900 (-20.40%) | 0.06% | $0 M | Nov 6, 2026 |
| 33 | HighMark Wealth Management LLC | 38,300 | -10,000 (-20.70%) | 0.06% | $0 M | Nov 17, 2026 |
| 34 | Millennium Management LLC | 36,140 | New | 0.06% | $0 M | Nov 16, 2026 |
| 35 | SEI Investments Co | 31,809 | 0 (0.00%) | 0.05% | $0 M | Nov 10, 2026 |
| 36 | Quadrature Capital Ltd | 30,775 | New | 0.05% | $0 M | Nov 13, 2026 |
| 37 | Rhumbline Advisers | 29,342 | -779 (-2.59%) | 0.05% | $0 M | Nov 10, 2026 |
| 38 | Connecticut Wealth Management, LLC | 22,303 | 0 (0.00%) | 0.04% | $0 M | Oct 13, 2026 |
| 39 | Jpmorgan Chase & Co | 22,139 | +1,931 (+9.56%) | 0.04% | $0 M | Nov 12, 2026 |
| 40 | MetLife Investment Management, LLC | 22,061 | -8,352 (-27.46%) | 0.04% | $0 M | Nov 16, 2026 |
| 41 | Provenance Wealth Advisors, LLC | 21,737 | New | 0.04% | $0 M | Oct 30, 2026 |
| 42 | MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. | 21,233 | -840 (-3.81%) | 0.03% | $0 M | Nov 16, 2026 |
| 43 | XTX Topco Ltd | 19,374 | +6,141 (+46.41%) | 0.03% | $0 M | Nov 16, 2026 |
| 44 | Virtu Financial LLC | 18,230 | New | 0.03% | $0 M | Nov 17, 2026 |
| 45 | Barclays PLC | 17,243 | +8,596 (+99.41%) | 0.03% | $0 M | Nov 6, 2026 |
| 46 | Police & Firemen's Retirement System of New Jersey | 16,200 | 0 (0.00%) | 0.03% | $0 M | Nov 9, 2026 |
| 47 | Russell Investments Group, Ltd. | 15,727 | +286 (+1.85%) | 0.03% | $0 M | Nov 6, 2026 |
| 48 | Cambridge Investment Research Advisors, Inc. | 15,554 | 0 (0.00%) | 0.03% | $0 M | Nov 2, 2026 |
| 49 | Vanguard Global Advisers, LLC | 15,486 | +218 (+1.43%) | 0.03% | $0 M | Nov 13, 2026 |
| 50 | Wells Fargo & Company/mn | 14,477 | -30,251 (-67.63%) | 0.02% | $0 M | Nov 16, 2026 |
| 51 | D. E. Shaw & Co., Inc. | 12,494 | New | 0.02% | $0 M | Nov 16, 2026 |
| 52 | New York State Common Retirement Fund | 11,095 | 0 (0.00%) | 0.02% | $0 M | Nov 17, 2026 |
| 53 | BNP Paribas Financial Markets | 10,572 | +3,373 (+46.85%) | 0.02% | $0 M | Nov 12, 2026 |
| 54 | Arax Advisory Partners | 5,991 | +144 (+2.46%) | 0.01% | $0 M | Nov 12, 2026 |
| 55 | Legal & General Group Plc | 4,666 | 0 (0.00%) | 0.01% | $0 M | Nov 16, 2026 |
| 56 | Ameritas Investment Partners, Inc. | 4,350 | 0 (0.00%) | 0.01% | $0 M | Nov 13, 2026 |
| 57 | Tower Research Capital LLC (TRC) | 3,248 | +130 (+4.17%) | 0.01% | $0 M | Nov 16, 2026 |
| 58 | FMR LLC | 2,472 | -86 (-3.36%) | 0.00% | $0 M | Nov 10, 2026 |
| 59 | Royal Bank Of Canada | 2,332 | +498 (+27.15%) | 0.00% | $0 M | Nov 16, 2026 |
| 60 | Citigroup Inc | 2,202 | -20,313 (-90.22%) | 0.00% | $0 M | Nov 4, 2026 |
| 61 | PNC Financial Services Group, Inc. | 1,956 | +1,813 (+1267.83%) | 0.00% | $0 M | Nov 6, 2026 |
| 62 | Sterling Capital Management LLC | 1,572 | +1,404 (+835.71%) | 0.00% | $0 M | Oct 22, 2026 |
| 63 | Hoertkorn Richard Charles | 668 | 0 (0.00%) | 0.00% | $0 M | Nov 4, 2026 |
| 64 | JDM Financial Group LLC | 530 | 0 (0.00%) | 0.00% | $0 M | Nov 17, 2026 |
| 65 | California State Teachers Retirement System | 393 | 0 (0.00%) | 0.00% | $0 M | Nov 13, 2026 |
| 66 | Allworth Financial LP | 297 | -7 (-2.30%) | 0.00% | $0 M | Nov 17, 2026 |
| 67 | Global Retirement Partners, LLC | 293 | New | 0.00% | $0 M | Nov 10, 2026 |
| 68 | EverSource Wealth Advisors, LLC | 226 | -14 (-5.83%) | 0.00% | $0 M | Nov 4, 2026 |
| 69 | SJS Investment Consulting Inc. | 213 | +201 (+1675.00%) | 0.00% | $0 M | Oct 26, 2026 |
| 70 | GAMMA Investing LLC | 193 | New | 0.00% | $0 M | Oct 8, 2026 |
| 71 | DiPaolo Financial Group, Inc. | 170 | New | 0.00% | $0 M | Nov 12, 2026 |
| 72 | Clearstead Advisors, LLC | 100 | 0 (0.00%) | 0.00% | $0 M | Nov 6, 2026 |
| 73 | Signaturefd, LLC | 100 | 0 (0.00%) | 0.00% | $0 M | Oct 23, 2026 |
| 74 | Essential Partners LLC | 92 | -3 (-3.16%) | 0.00% | $0 M | Oct 14, 2026 |
| 75 | Farther Finance Advisors, LLC | 80 | +2 (+2.56%) | 0.00% | $0 M | Oct 8, 2026 |
| 76 | True Wealth Design, LLC | 66 | -12 (-15.38%) | 0.00% | $0 M | Oct 13, 2026 |
| 77 | Fortitude Family Office, LLC | 28 | 0 (0.00%) | 0.00% | $0 M | Oct 14, 2026 |
| 78 | Root Financial Partners, LLC | 16 | New | 0.00% | $0 M | Oct 21, 2026 |
| 79 | SBI Securities Co., Ltd. | 12 | New | 0.00% | $0 M | Oct 22, 2026 |
| 80 | Rothschild Investment LLC | 9 | -60 (-86.96%) | 0.00% | $0 M | Nov 10, 2026 |
| 81 | IFP Advisors, Inc | 7 | -44 (-86.27%) | 0.00% | $0 M | Oct 16, 2026 |
| 82 | Caitong International Asset Management Co., Ltd | 2 | +1 (+100.00%) | 0.00% | $0 M | Oct 29, 2026 |
Mutual funds holding TriSalus Life Sciences, Inc.#
| Fund | Shares | Value | Of the company | Of the fund | Change in shares | Report |
|---|---|---|---|---|---|---|
| 🇺🇸 Vanguard Total Stock Market Index FundThe Vanguard Group, Inc. | 1.14 M | $5 M | 1.9% | <0.01% | +27% | Jun 30, 2026 |
| 🇺🇸 iShares Russell 2000 ETFBlackRock Fund Advisors | 1.12 M | $5 M | 1.8% | <0.01% | +73% | Jun 30, 2026 |
| 🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc. | 545,765 | $2 M | 0.88% | <0.01% | +41% | Jun 30, 2026 |
| 🇺🇸 Fidelity Small Cap Index FundFidelity Management & Research Company LLC | 521,754 | $2 M | 0.85% | <0.01% | +90% | Jul 31, 2026 |
| 🇺🇸 iShares Russell 2000 Growth ETFBlackRock Fund Advisors | 450,180 | $2 M | 0.73% | 0.01% | +712% | Jun 30, 2026 |
| 🇺🇸 Royce Smaller-Companies Growth FundRoyce & Associates, LP | 200,000 | $1 M | 0.32% | 0.38% | no change | Jun 30, 2026 |
| 🇺🇸 iShares Micro-Cap ETFBlackRock Fund Advisors | 160,188 | $1 M | 0.26% | 0.05% | +126% | Jun 30, 2026 |
| 🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC | 189,776 | $1 M | 0.31% | <0.01% | +0.3% | May 31, 2026 |
| 🇺🇸 Schwab Small-Cap Index FundCharles Schwab Investment Management, Inc. | 116,669 | $1 M | 0.19% | <0.01% | +97% | Jul 31, 2026 |
| 🇺🇸 Vanguard Russell 2000 Index FundThe Vanguard Group, Inc. | 143,142 | $0 M | 0.23% | <0.01% | −4.6% | May 31, 2026 |
| 🇺🇸 Master Small Cap Index SeriesBlackRock Advisors, LLC | 89,608 | $0 M | 0.15% | <0.01% | +224% | Jun 30, 2026 |
| 🇺🇸 Ultra-Small Company Market FundBridgeway Capital Management, LLC | 65,000 | $0 M | 0.11% | 0.20% | no change | Jun 30, 2026 |
| 🇺🇸 Nuveen Small Cap Blend Index FundTeachers Advisors, LLC | 63,898 | $0 M | 0.10% | <0.01% | +75% | Jul 31, 2026 |
| 🇺🇸 Goldman Sachs Absolute Return Tracker FundGoldman Sachs Asset Management, L.P. | 56,111 | $0 M | 0.09% | <0.01% | +149% | Jun 30, 2026 |
| 🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC | 68,501 | $0 M | 0.11% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 EQ/2000 Managed Volatility PortfolioEquitable Investment Management Group, LLC | 49,491 | $0 M | 0.08% | <0.01% | +60% | Jun 30, 2026 |
| 🇺🇸 Fidelity Small Cap Growth Index FundFidelity Management & Research Company LLC | 44,692 | $0 M | 0.07% | 0.01% | +776% | Jun 30, 2026 |
| 🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC | 53,913 | $0 M | 0.09% | <0.01% | +6.2% | May 31, 2026 |
| 🇺🇸 LVIP State Street Small-Cap Index FundLincoln Financial Investments Corporation | 35,700 | $0 M | 0.06% | <0.01% | +130% | Jun 30, 2026 |
| 🇺🇸 Fidelity Nasdaq Composite Index FundFidelity Management & Research Company LLC | 39,480 | $0 M | 0.06% | <0.01% | +15% | May 31, 2026 |
| 🇺🇸 Small Cap Index FundNorthern Trust Investments, Inc. | 24,964 | $0 M | 0.04% | <0.01% | +153% | Jun 30, 2026 |
| 🇺🇸 Global X Russell 2000 ETFGlobal X Management Company LLC | 22,914 | $0 M | 0.04% | <0.01% | +88% | Jul 31, 2026 |
| 🇺🇸 Vanguard Balanced Index FundThe Vanguard Group, Inc. | 21,096 | $0 M | 0.03% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Vanguard Institutional Total Stock Market Index FundThe Vanguard Group, Inc. | 20,654 | $0 M | 0.03% | <0.01% | −49% | Jun 30, 2026 |
| 🇺🇸 MetLife Russell 2000 Index PortfolioBrighthouse Investment Advisers, LLC | 17,243 | $0 M | 0.03% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Small-Cap Index PortfolioPacific Life Fund Advisors LLC | 14,339 | $0 M | 0.02% | <0.01% | +87% | Jun 30, 2026 |
| 🇺🇸 Vanguard Russell 2000 Value Index FundThe Vanguard Group, Inc. | 17,689 | $0 M | 0.03% | <0.01% | +4.4% | May 31, 2026 |
| 🇺🇸 State Street Small/mid Cap Equity Index PortfolioSSGA Funds Management, Inc. | 11,300 | $0 M | 0.02% | <0.01% | +13% | Jun 30, 2026 |
| 🇺🇸 1290 VT Micro Cap PortfolioEquitable Investment Management Group, LLC | 10,760 | $0 M | 0.02% | 0.02% | +116% | Jun 30, 2026 |
| 🇺🇸 Bridge Builder Small/Mid Cap Value FundOLIVE STREET INVESTMENT ADVISERS LLC | 10,619 | $0 M | 0.02% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 ATM Small Cap Managed Volatility PortfolioEquitable Investment Management Group, LLC | 10,264 | $0 M | 0.02% | <0.01% | +63% | Jun 30, 2026 |
| 🇺🇸 NVIT Small Cap Index FundNATIONWIDE FUND ADVISORS | 9,775 | $0 M | 0.02% | <0.01% | +106% | Jun 30, 2026 |
| 🇺🇸 Small Cap Index FundThe Variable Annuity Life Insurance Company | 11,389 | $0 M | 0.02% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 DWS Small Cap Index VIPDWS Investment Management Americas, Inc. | 7,527 | $0 M | 0.01% | <0.01% | +83% | Jun 30, 2026 |
| 🇺🇸 T. Rowe Price Small-Cap Index FundT. Rowe Price Associates, Inc. | 7,228 | $0 M | 0.01% | <0.01% | +109% | Jun 30, 2026 |
| 🇺🇸 EQ/Morgan Stanley Small Cap Growth PortfolioEquitable Investment Management Group, LLC | 7,188 | $0 M | 0.01% | <0.01% | +864% | Jun 30, 2026 |
| 🇺🇸 BlackRock Small Cap Index V.I. FundBlackRock Advisors, LLC | 6,774 | $0 M | 0.01% | <0.01% | +86% | Jun 30, 2026 |
| 🇺🇸 Voya RussellTM Small Cap Index PortfolioVoya Investments, LLC | 6,174 | $0 M | 0.01% | <0.01% | +92% | Jun 30, 2026 |
| 🇺🇸 SA Small Cap Index PortfolioSunAmerica Asset Management, LLC | 5,614 | $0 M | <0.01% | <0.01% | +64% | Jul 31, 2026 |
| 🇺🇸 Vanguard Russell 2000 Growth Index FundThe Vanguard Group, Inc. | 6,659 | $0 M | 0.01% | <0.01% | +2.9% | May 31, 2026 |
| 🇺🇸 Nationwide Small Cap Index FundNATIONWIDE FUND ADVISORS | 4,450 | $0 M | <0.01% | <0.01% | +85% | Jul 31, 2026 |
| 🇺🇸 iShares Russell Small/Mid-Cap Index FundBlackRock Advisors, LLC | 4,408 | $0 M | <0.01% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 CVT Russell 2000 Small Cap Index PortfolioCalvert Research and Management | 4,350 | $0 M | <0.01% | <0.01% | +167% | Jun 30, 2026 |
| 🇺🇸 PD Small-Cap Growth Index PortfolioPacific Life Fund Advisors LLC | 4,339 | $0 M | <0.01% | 0.01% | +1608% | Jun 30, 2026 |
| 🇺🇸 EQ/AB Small Cap Growth PortfolioEquitable Investment Management Group, LLC | 4,030 | $0 M | <0.01% | <0.01% | +595% | Jun 30, 2026 |
| 🇺🇸 EQ/Small Company Index PortfolioEquitable Investment Management Group, LLC | 4,030 | $0 M | <0.01% | <0.01% | +595% | Jun 30, 2026 |
| 🇺🇸 Venerable Small Cap Index FundVenerable Investment Advisers, LLC | 3,824 | $0 M | <0.01% | <0.01% | +189% | Jun 30, 2026 |
| 🇺🇸 SmallCap Growth Fund IPrincipal Global Investors, LLC | 3,665 | $0 M | <0.01% | <0.01% | +404% | Jul 31, 2026 |
| 🇺🇸 Voya VACS Index Series SC PortfolioVoya Investments, LLC | 3,620 | $0 M | <0.01% | <0.01% | +82% | Jun 30, 2026 |
| 🇺🇸 Nationwide Fundamental All Cap Equity PortfolioNATIONWIDE FUND ADVISORS | 3,534 | $0 M | <0.01% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 EQ/Franklin Small Cap Value Managed Volatility PortfolioEquitable Investment Management Group, LLC | 2,227 | $0 M | <0.01% | <0.01% | +155% | Jun 30, 2026 |
| 🇺🇸 Vanguard Russell 3000 Index FundThe Vanguard Group, Inc. | 2,257 | $0 M | <0.01% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 State Street Total Return V.I.S. FundSSGA Funds Management, Inc. | 1,397 | $0 M | <0.01% | <0.01% | +110% | Jun 30, 2026 |
| 🇺🇸 ProShares Russell 2000 High Income ETFPROSHARE ADVISORS LLC | 1,321 | $0 M | <0.01% | <0.01% | +0.4% | May 31, 2026 |
| 🇺🇸 Bridge Builder Small/Mid Cap Growth FundOLIVE STREET INVESTMENT ADVISERS LLC | 998 | $0 M | <0.01% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 ProShares UltraPro Russell2000PROSHARE ADVISORS LLC | 1,044 | $0 M | <0.01% | <0.01% | −44% | May 31, 2026 |
| 🇺🇸 ProShares Ultra Russell2000PROSHARE ADVISORS LLC | 1,033 | $0 M | <0.01% | <0.01% | −45% | May 31, 2026 |
| 🇺🇸 Destinations Small-Mid Cap Equity FundBrinker Capital Investments, LLC | 666 | $0 M | <0.01% | <0.01% | new | May 31, 2026 |
| 🇺🇸 Knights of Columbus U.S. ALL CAP INDEX FUNDKnights of Columbus Asset Advisors LLC | 209 | $0 M | <0.01% | <0.01% | +48% | Jul 31, 2026 |
Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jul 31, 2026. The 59 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.
Insider trading at TriSalus Life Sciences, Inc.#
Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.
| Traded | Insider | Trade | Shares | Price | Value | Owned after | Filing |
|---|---|---|---|---|---|---|---|
| filed | Richard MarshakChief Commercial Officer | Sell | -544 | $2.430 | $1 K | 127,450 | Form 4 |
| filed | Mats WahlstromDirector | Buy | +50,000 | $2.240 | $112 K | 197,555 | Form 4 |
| filed | Jennifer StevensChief Regulatory Officer | Sell | -316 | $4.390 | $1 K | 123,794 | Form 4 |
| filed | Richard MarshakChief Commercial Officer | Sell | -325 | $4.390 | $1 K | 127,994 | Form 4 |
| filed | Bryan F. CoxChief of Research | Sell | -296 | $4.390 | $1 K | 162,805 | Form 4 |
| filed | Mary T. SzelaCEO and President, Director | Shares withheld for tax | -2,693 | $4.380 | $12 K | 1.07 M | Form 4 |
| filed | David PatienceChief Financial Officer | Shares withheld for tax | -14,650 | $4.460 | $65 K | 261,107 | Form 4 |
| filed | Mary T. SzelaCEO and President, Director | Grant or award | +3,990 | $3.870 | $15 K | 1.08 M | Form 4 |
Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals
Markets and events: TriSalus Life Sciences, Inc.#
Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.
Trading halts
- 2026-05-13 13:37 UTC, code LUDP, resumed 13:42 UTC
- 2026-05-13 13:31 UTC, code LUDP, resumed 13:36 UTC
Fails to deliver
- : 910 shares at $3.80
- : 115 shares at $3.62
- : 2,643 shares at $3.53
- : 424 shares at $4.14
- : 12 shares at $5.00
Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables
TriSalus Life Sciences, Inc. scorecard#
Passes 5 of the 17 checks that could be worked out: strongest in growth (3 of 4), weakest in valuation (0 of 5). Fiscal year 2025; market cap of Oct 28, 2026.
Valuation0 of 5
- ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
- ✗Price to book below its peers' medianNo price to bookShareholders' equity is negative.
- ✗Price to sales below its peers' median5.0×Price to sales 5.0× against Healthcare's median of 3.8×.
- ✗Free cash flow yield above 5%-8.1%Free cash flow is -8.1% of the market value.
- ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 5.15% (2026-11-13).
- –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
Growth3 of 4
- ✓Revenue grew in the newest year53.4%Revenue up 53.4% in fiscal 2025.
- ✓Revenue up more than 5% a year over three years53.8%53.8% a year over the three years to fiscal 2025.
- ✓Faster growth over three years than its peers' median53.8%53.8% a year against Healthcare's median of 8.5% (549 companies).
- ✗Earnings per share grew in the newest year-1.84 vs -1.31Diluted EPS -1.84 in fiscal 2025 against -1.31 the year before (report's currency).
- –Net income higher than five years earlierNet income of five years earlier is not on file.
- –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
Profitability1 of 4
- ✗Profitable in the newest year-$39 MNet income -$39 M in fiscal 2025.
- ✗Profitable in each of the last five years1 of 5Profitable in 1 of the five years to fiscal 2025.
- ✗Operating margin above its peers' median-59.7%-59.7% against Healthcare's median of -7.7% (674 companies).
- –Return on equity above 15%No return on equity (equity missing or negative).
- –Return on invested capital above 10%No return on invested capital on file.
- ✓Operating margin wider than three years earlier-59.7%-59.7% in fiscal 2025 against -293.9% in 2022.
Financial health1 of 3
- ✓Short-term assets cover short-term liabilities2.8×Current ratio 2.80 at the end of fiscal 2025.
- –Debt below equityDebt or equity is not on file (or equity is negative).
- –Net debt below three years of EBITDANet debt to EBITDA is not on file.
- –Operating income covers interest five timesInterest expense is not on file.
- ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
- ✗Altman Z-score outside the distress zone-11.60Z-score -11.60 (distress zone) for fiscal 2025.
Shareholder returns0 of 1
- –Pays a dividendDividends are not on file.
- –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
- –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
- ✗Share count up no more than 2% in a year49.6%Diluted shares up 49.6% in fiscal 2025.
- –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
- –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.
Worked out from the statements as filed (sec), the medians of Healthcare, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work
Financial analysis, 2025#
Worked out from TriSalus Life Sciences, Inc.'s statements, beside the median of Healthcare.
| Ratio | Trend | 2025 | Median of peers |
|---|---|---|---|
| Operating margin | -59.7% | -7.7% | |
| Net margin | -86.9% | -8.1% | |
| Revenue growth, 3 years a year | 53.8% | 8.5% | |
| Revenue growth | 53.4% | 10.2% | |
| Free cash flow margin | -41.9% | -1.3% |
4of 9on the Piotroski tests of financial strength
- Net loss of $39 million, the 4th loss-making year in a row.
- Free cash flow was negative: -$19 million.
- The share count rose 49.6% in the year.
- Shareholders' equity is negative: -$34 million.
TriSalus Life Sciences, Inc.: financial statements#
Income statement, balance sheet and cash-flow statement as reported, newest period first.
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | FY 2025to Dec 31, 2025 | FY 2024to Dec 31, 2024 | FY 2023to Dec 31, 2023 | FY 2022to Dec 31, 2022 | FY 2021to Dec 31, 2021 |
|---|---|---|---|---|---|---|
| Income statement | ||||||
| Revenue | 45+53.4%100% | 29+59.0%100% | 19+49.3%100% | 12—100% | — | |
| Cost of revenue | 7.0+69.8%15.4% | 4.1+57.5%13.9% | 2.6+15.4%14.1% | 2.3—18.2% | — | |
| Gross profit | 38+50.8%84.6% | 25+59.2%86.1% | 16+56.9%85.9% | 10—81.8% | — | |
| Research and development | 15−15.4%33.1% | 18−40.7%60.1% | 30r30+39.7%161% | 21—172% | — | |
| Selling and marketing | 29+11.1%63.6% | 26+51.7%87.8% | 17+33.7%92.0% | 13—103% | — | |
| General and administrative | 21+19.4%47.5% | 18−23.6%61.0% | 24+88.4%127% | 12r2.7+311%101% | 3.0—— | |
| Operating income | −27—−59.7% | −36—−123% | −54r−54—−294% | −36r−2.7—−294% | −3.0—— | |
| Interest and finance income | 0.6+37.4%1.2% | 0.4−6.3%1.4% | 0.4+139%2.3% | 0.2r3.0+181%1.5% | 0.1—— | |
| Interest expense and finance costs | 5.5+79.4%12.3% | 3.1+19213%10.5% | 0.0+1500%0.1% | 0.0—0.0% | — | |
| Other non-operating income (expense) | −0.5—−1.0% | −0.3—−1.1% | −0.4r−0.4−104%−2.0% | 8.9+13.4%71.4% | 7.8—— | |
| Income before tax | −39—−86.9% | −30—−102% | −59r−59—−321% | −47r6.1−1090%−381% | 4.8—— | |
| Income tax | 0.0+16.7%0.0% | 0.0−33.3%0.0% | 0.00.0%0.0% | 0.0r0.6—0.1% | 0—— | |
| Net income including minority interests | — | — | — | 5.5+16.2%44.7% | 4.8—— | |
| Net income attributable to shareholders | −39—−86.9% | −30—−102% | −59r−59—−321% | −47r5.5−1090%−381% | 4.8—— | |
| Earnings per share, basic | -1.84—— | -1.31—— | -6.77r-6.73—— | -161.55—— | — | |
| Earnings per share, diluted | -1.84—— | -1.31—— | -6.77r-6.73—— | -161.55—— | — | |
| Shares, weighted average (basic) | 38+49.6%— | 25+170%— | 9.4+2935%— | 0.3—— | — | |
| Shares, weighted average (diluted) | 38+49.6%— | 25+170%— | 9.4+2935%— | 0.3—— | — | |
| Balance sheet | ||||||
| Cash and cash equivalents | 20+140%57.9% | 8.5−27.6%35.6% | 12+25.1%47.9% | 9.4r0.2+4586%42.8% | 0.2—0.1% | |
| Receivables | 6.6+28.9%18.6% | 5.1+43.1%21.2% | 3.6+128%14.4% | 1.6—7.1% | — | |
| Inventory | 3.1−24.0%8.7% | 4.0+59.1%16.9% | 2.5+73.0%10.3% | 1.5—6.7% | — | |
| Current assets | 32+56.0%91.3% | 21−0.9%86.2% | 21+21.2%84.8% | 17r0.4+3173%78.3% | 0.5—0.2% | |
| Property, plant and equipment | 1.8+8.3%5.1% | 1.7−20.2%7.0% | 2.1−6.3%8.5% | 2.2—10.1% | — | |
| Right-of-use (leased) assets | 0.9−28.8%2.4% | 1.2+2.6%5.0% | 1.2−14.6%4.8% | 1.4—6.3% | — | |
| Other intangible assets | — | — | 0r1.1−100%0.0% | 0.8—3.6% | — | |
| Total assets | 35+47.4%100% | 24−2.5%100% | 25r26+11.8%100% | 22r20−91.2%100% | 251—100% | |
| Accounts payable | 3.0+32.0%8.5% | 2.3−32.9%9.5% | 3.4−31.5%13.8% | 4.9r1.4+368%22.5% | 1.1—0.4% | |
| Current liabilities | 11+12.4%32.5% | 10−30.4%42.7% | 15−54.6%59.7% | 32r2.5+1920%147% | 1.6—0.6% | |
| Long-term debt | 33+49.6%93.5% | 22—92.1% | 0—0.0% | — | — | |
| Lease liabilities (non-current) | 1.2−9.5%3.4% | 1.3+13.4%5.5% | 1.2—4.7% | — | — | |
| Total liabilities | 69+38.8%196% | 50−3.5%208% | 52+50.5%210% | 34r14+98.9%156% | 17—6.9% | |
| Retained earnings | −331—−936% | −280—−1166% | −250r−248—−1014% | −186r−13—−847% | −17—−6.7% | |
| Shareholders' equity | −34—−95.8% | −26—−108% | −27r−26—−110% | −177r−13—−805% | −130r−17—−51.7% | |
| Total liabilities and equity | 35+47.4%100% | 24−2.5%100% | 25r26+11.8%100% | 22r20−91.2%100% | 251—100% | |
| Shares outstanding | 50+59.8%— | 31+18.4%— | 26+7492%— | 0.3—— | — | |
| Cash-flow statement | ||||||
| Depreciation and amortization | 0.6−15.9%1.4% | 0.7+8.8%2.5% | 0.7r0.7+71.9%3.7% | 0.4—3.2% | — | |
| Share-based compensation | 9.1+67.8%20.2% | 5.4+288%18.5% | 1.4+281%7.6% | 0.4—3.0% | — | |
| Cash from operating activities | −18—−39.9% | −41—−139% | −51r−50—−273% | −32r−2.7—−261% | −1.7—— | |
| Capital expenditure | −0.9—−2.0% | −0.3—−1.2% | −0.6—−3.2% | −0.7—−5.3% | — | |
| Intangible assets bought | — | — | 0r−0.5—0.0% | −0.1—−1.1% | — | |
| Cash from investing activities | −0.8—−1.9% | −0.3—−1.2% | −1.6r−2.1—−8.6% | −1.8r233−3077%−14.4% | 0.1—— | |
| Shares issued | 22+45.7%48.7% | 15r16—51.3% | 0—0.0% | — | — | |
| Shares bought back | — | — | — | −232—−1874% | — | |
| Cash from financing activities | 31−18.9%68.1% | 38−30.6%129% | 55+306%295% | 13r−231+2375%109% | 0.5—— | |
| Change in cash | 12—26.4% | −3.3−232%−11.0% | 2.5—13.3% | −21r−0.0—−166% | −1.1—— | |
| Report | 10-K | 10-K | 10-K/A | 10-K | 10-K | |
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the same quarter a year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | Last 12 months4 quarters to Sep 30, 2026 | Q3 FY2026to Sep 30, 2026 | Q2 FY2026to Jun 30, 2026 | Q1 FY2026to Mar 31, 2026 | Q4 FY2025to Dec 31, 2025 | Q3 FY2025to Sep 30, 2025 | Q2 FY2025to Jun 30, 2025 | Q1 FY2025to Mar 31, 2025 | Q4 FY2024to Dec 31, 2024 | Q3 FY2024to Sep 30, 2024 | Q2 FY2024to Jun 30, 2024 | Q1 FY2024to Mar 31, 2024 | Q4 FY2023to Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||||||
| Revenue | 46+15.4%100% | 13+11.3%100% | 11+1.7%100% | 8.9−2.9%100% | 13*+59.8%100% | 12+57.4%100% | 11+52.3%100% | 9.2+42.0%100% | 8.3*+44.4%100% | 7.3—100% | 7.4—100% | 6.5—100% | 5.7*—100% | |
| Cost of revenue | 6.3−2.1%13.5% | 1.8−6.5%13.8% | 1.5−16.3%13.2% | 1.2−17.7%13.8% | 1.8*+44.9%13.3% | 1.9+89.8%16.5% | 1.8+97.6%16.1% | 1.5+54.0%16.3% | 1.2*+109%14.7% | 1.0—13.7% | 0.9—12.4% | 1.0—15.0% | 0.6*—10.2% | |
| Gross profit | 40+18.7%86.5% | 11+14.9%86.2% | 9.9+5.2%86.8% | 7.7−0.0%86.2% | 11*+62.4%86.7% | 9.7+52.2%83.5% | 9.4+45.9%83.9% | 7.7+39.8%83.7% | 7.0*+37.1%85.3% | 6.3—86.3% | 6.5—87.6% | 5.5—85.0% | 5.1*—89.8% | |
| Research and development | 12−21.1%26.1% | 3.2−44.1%24.8% | 3.1−14.5%27.5% | 3.2+6.5%36.1% | 2.6*−13.1%19.5% | 5.7r5.2+35.2%49.3% | 3.7r3.9−21.3%32.7% | 3.0r3.3−48.3%33.0% | 3.0*−61.9%35.8% | 4.2—57.4% | 4.7—63.4% | 5.8r5.9—90.5% | 7.8r7.6*—136% | |
| Selling and marketing | 38+35.3%80.9% | 11+56.9%83.3% | 11+59.4%100% | 7.4+10.1%83.3% | 8.0*+13.7%60.4% | 6.8+11.4%59.1% | 7.2+19.3%63.9% | 6.7+0.7%73.5% | 7.0*+25.1%84.9% | 6.1—83.5% | 6.0—81.5% | 6.7—104% | 5.6*—98.0% | |
| General and administrative | 20−10.4%42.4% | 4.9−20.4%37.9% | 5.2−12.7%45.2% | 5.5+3.9%61.3% | 4.2*−10.4%31.6% | 6.1r6.7+29.7%53.0% | 5.9r5.7+49.4%52.7% | 5.2r5.0+13.4%57.2% | 4.7*−22.6%56.4% | 4.7—64.3% | 4.0—53.7% | 4.6—71.7% | 6.0*—105% | |
| Operating income | −29—−63.0% | −7.7—−59.9% | −9.8—−86.0% | −8.4—−94.5% | −3.3*—−24.8% | −9.0—−77.9% | −7.3—−65.4% | −7.3—−79.9% | −7.6*—−91.8% | −8.7—−119% | −8.2—−111% | −12r−12—−181% | −14r−14*—−249% | |
| Interest and finance income | 1.2+171%2.5% | 0.4+125%3.0% | 0.5+241%4.0% | 0.2+122%1.8% | 0.2*+211%1.3% | 0.2+7.6%1.5% | 0.1+38.1%1.2% | 0.1−19.6%0.8% | 0.1*−76.6%0.7% | 0.2—2.1% | 0.1—1.3% | 0.1—1.4% | 0.2*—4.3% | |
| Interest expense and finance costs | 5.9+15.1%12.8% | 1.6+6.8%12.1% | 1.5+4.7%13.1% | 1.4+18.8%16.1% | 1.5*+36.0%11.0% | 1.5+27.8%12.6% | 1.4+62.3%12.7% | 1.2+40200%13.2% | 1.1*+35500%12.9% | 1.1—15.5% | 0.9—11.9% | 0.0—0.0% | 0.0*—0.1% | |
| Other non-operating income (expense) | −0.1—−0.2% | −0.1—−0.4% | 0.1—0.8% | −0.1—−0.9% | −0.1*—−0.5% | −0.1—−0.8% | −0.0—−0.4% | −0.3—−2.7% | −0.1*—−1.2% | −0.0—−0.2% | −0.0—−0.6% | −0.2—−2.4% | −0.3r−0.3*—−5.6% | |
| Income before tax | −26—−56.6% | −8.9—−68.7% | −9.2—−80.5% | 1.5—17.3% | −9.8*—−73.9% | −11—−93.4% | −8.3—−73.9% | −10—−113% | −10*—−122% | −2.4—−32.7% | −4.3—−58.7% | −13r−13—−204% | −36r−36*—−623% | |
| Income tax | 0.0+100%0.0% | 0.0−20.0%0.0% | 0.0—0.0% | 0.0−20.0%0.0% | 0*—0.0% | 0.0—0.0% | −0.0−143%−0.0% | 0.0+66.7%0.1% | −0.0*−200%−0.0% | −0.0—−0.0% | 0.0—0.1% | 0.0—0.0% | 0.0*—0.0% | |
| Net income attributable to shareholders | −26—−56.6% | −8.9—−68.8% | −9.2—−80.5% | 1.5—17.3% | −9.8*—−73.9% | −11—−93.5% | −8.3—−73.9% | −10—−113% | −10*—−122% | −2.4—−32.6% | −4.3—−58.8% | −13r−13—−205% | −36r−36*—−623% | |
| Earnings per share, basic | — | -0.15—— | -0.16—— | 0.03—— | — | -0.96—— | -0.27—— | -0.39—— | — | -0.12—— | -0.21—— | -0.60—— | — | |
| Earnings per share, diluted | — | -0.15—— | -0.16—— | 0.03—— | — | -0.96—— | -0.27—— | -0.39—— | — | -0.12—— | -0.21—— | -0.60—— | — | |
| Shares, weighted average (basic) | 58+35.8%— | 58+35.8%— | 58+77.2%— | 52+80.7%— | — | 43+62.5%— | 33+37.6%— | 29+22.3%— | — | 27—— | 24—— | 23—— | — | |
| Shares, weighted average (diluted) | 58+35.8%— | 58+35.8%— | 58+77.2%— | 52+83.4%— | — | 43+62.5%— | 33+37.6%— | 29+22.3%— | — | 27—— | 24—— | 23—— | — | |
| Balance sheet | ||||||||||||||
| Cash and cash equivalents | 41—71.3% | 41+81.0%71.3% | 46+74.7%74.1% | 57+335%79.7% | 20+140%57.9% | 23+101%62.2% | 26+60.7%64.1% | 13+227%45.4% | 8.5−27.6%35.6% | 11—41.1% | 16—50.8% | 4.0—22.2% | 12—47.9% | |
| Receivables | 6.1—10.6% | 6.1+22.5%10.6% | 6.5+15.9%10.3% | 5.2−4.4%7.3% | 6.6+28.9%18.6% | 5.0+1.8%13.7% | 5.6+18.4%13.5% | 5.5+27.5%19.0% | 5.1+43.1%21.2% | 4.9—17.9% | 4.7—14.5% | 4.3—23.9% | 3.6—14.4% | |
| Inventory | 4.6—8.1% | 4.6+41.6%8.1% | 4.2+10.5%6.7% | 3.8−9.2%5.3% | 3.1−24.0%8.7% | 3.3−18.1%9.0% | 3.8+10.6%9.2% | 4.2+42.9%14.5% | 4.0+59.1%16.9% | 4.0—14.6% | 3.4—10.6% | 2.9—16.3% | 2.5—10.3% | |
| Current assets | 55—95.4% | 55+64.7%95.4% | 60+56.9%95.7% | 68+172%96.0% | 32+56.0%91.3% | 33+40.0%91.4% | 38+36.3%92.2% | 25+90.3%87.7% | 21−0.9%86.2% | 24—86.6% | 28—86.2% | 13—73.7% | 21—84.8% | |
| Property, plant and equipment | 1.8—3.2% | 1.8+0.2%3.2% | 1.8+7.4%2.9% | 1.9−1.3%2.7% | 1.8+8.3%5.1% | 1.8+0.4%5.0% | 1.7−6.5%4.1% | 2.0+0.2%6.9% | 1.7−20.2%7.0% | 1.8—6.6% | 1.8—5.6% | 2.0—11.0% | 2.1—8.5% | |
| Right-of-use (leased) assets | 0.8—1.3% | 0.8−13.9%1.3% | 0.8−27.7%1.3% | 0.8−27.0%1.2% | 0.9−28.8%2.4% | 0.9−37.6%2.4% | 1.1−1.8%2.7% | 1.1−4.9%4.0% | 1.2+2.6%5.0% | 1.4—5.2% | 1.1—3.5% | 1.2—6.7% | 1.2—4.8% | |
| Other intangible assets | — | — | — | — | — | — | — | — | — | — | 1.1—3.4% | 1.1—6.2% | 0r1.1—0.0% | |
| Total assets | 58—100% | 58+57.9%100% | 62+51.1%100% | 71+148%100% | 35+47.4%100% | 36+32.7%100% | 41+27.4%100% | 29+60.0%100% | 24−2.5%100% | 27—100% | 32—100% | 18—100% | 25r26—100% | |
| Accounts payable | 4.2—7.4% | 4.2+11.8%7.4% | 3.8+97.8%6.0% | 4.2+50.8%6.0% | 3.0+32.0%8.5% | 3.8+162%10.4% | 1.9−3.7%4.6% | 2.8+19.5%9.8% | 2.3−32.9%9.5% | 1.4—5.3% | 2.0—6.1% | 2.3—13.1% | 3.4—13.8% | |
| Current liabilities | 13—22.6% | 13+19.3%22.6% | 11+19.8%17.9% | 12+0.3%16.6% | 11+12.4%32.5% | 11+10.0%29.9% | 9.3−22.3%22.6% | 12−18.3%41.1% | 10−30.4%42.7% | 9.9—36.1% | 12—37.0% | 14—80.5% | 15—59.7% | |
| Long-term debt | 32—56.2% | 32−1.2%56.2% | 33+2.5%52.9% | 33+4.4%46.6% | 33+49.6%93.5% | 33+51.1%89.9% | 32+51.6%78.1% | 32—111% | 22—92.1% | 22—78.9% | 21—65.6% | — | 0—0.0% | |
| Lease liabilities (non-current) | — | — | — | — | 1.2−9.5%3.4% | — | — | — | 1.3+13.4%5.5% | — | — | — | 1.2—4.7% | |
| Total liabilities | 57—98.8% | 57−10.0%98.8% | 56−8.0%89.5% | 58−7.7%82.0% | 69+38.8%196% | 63+31.9%173% | 61+7.4%147% | 63+19.3%220% | 50−3.5%208% | 48—174% | 57—174% | 53—295% | 52—210% | |
| Retained earnings | −347—−603% | −347—−603% | −338—−542% | −329—−464% | −331—−936% | −321—−880% | −298—−722% | −290—−1013% | −280—−1166% | −269—−981% | −266—−820% | −262—−1462% | −250r−248—−1014% | |
| Shareholders' equity | 0.7—1.2% | 0.7—1.2% | 6.6—10.5% | 13—18.0% | −34—−95.8% | −27—−73.3% | −19—−47.0% | −34—−120% | −26—−108% | −20—−74.4% | −25r−24—−77.9% | −36r−35—−201% | −27r−26—−110% | |
| Total liabilities and equity | 58—100% | 58+57.9%100% | 62+51.1%100% | 71+148%100% | 35+47.4%100% | 36+32.7%100% | 41+27.4%100% | 29+60.0%100% | 24−2.5%100% | 27—100% | 32—100% | 18—100% | 25r26—100% | |
| Shares outstanding | 62—— | 62+23.6%— | 61+61.8%— | 61+90.3%— | 50+59.8%— | 50+63.7%— | 38+39.9%— | 32+20.6%— | 31+18.4%— | 30—— | 27—— | 27—— | 26—— | |
| Cash-flow statement | ||||||||||||||
| Depreciation and amortization | 0.5−24.1%1.1% | 0.1*−20.9%1.0% | 0.1*−17.6%1.2% | 0.1−21.5%1.5% | 0.1*−34.7%1.0% | 0.2*−10.4%1.4% | 0.2*−14.9%1.5% | 0.2−1.7%1.9% | 0.2*−0.5%2.3% | 0.2r0.2*—2.5% | 0.2r0.2*—2.6% | 0.2r0.2—2.7% | 0.2r0.2*—3.4% | |
| Share-based compensation | 10+17.2%21.8% | 2.8*−17.2%22.0% | 2.6*+38.3%22.9% | 2.5+52.6%27.8% | 2.2*+29.5%16.6% | 3.4*+147%29.6% | 1.9*+48.4%16.9% | 1.6+49.2%17.7% | 1.7*+69.7%20.5% | 1.4*—18.8% | 1.3*—17.3% | 1.1—16.8% | 1.0*—17.5% | |
| Cash from operating activities | −24—−52.5% | −5.3*—−41.0% | −10*—−88.8% | −6.5—−72.8% | −2.5*—−18.8% | −3.7*—−32.1% | −7.3*—−65.3% | −4.5—−49.1% | −5.7*—−69.1% | −11*—−148% | −13*—−182% | −11—−168% | −9.2r−8.8*—−160% | |
| Capital expenditure | −0.4—−0.8% | −0.1*—−0.7% | −0.1*—−0.7% | −0.1—−1.6% | −0.0*—−0.3% | −0.2*—−1.9% | — | −0.8—−8.2% | −0.1*—−0.6% | −0.2*—−2.3% | −0.1*—−0.8% | −0.1—−1.0% | −0.4*—−6.5% | |
| Intangible assets bought | — | — | — | — | — | — | — | — | — | — | 0*—0.0% | 0—0.0% | 0r−0.3*—0.0% | |
| Cash from investing activities | −0.4—−0.8% | −0.1*—−0.7% | −0.1*−188%−0.7% | −0.1—−1.6% | −0.0*—−0.3% | −0.2*—−1.5% | 0.1*—0.8% | −0.7—−7.8% | −0.1*—−0.6% | −0.2*—−2.3% | −0.1*—−0.8% | −0.1—−1.0% | −0.4r−0.7*—−6.5% | |
| Shares issued | 44+92.3%95.2% | 0*—0.0% | 0*−100%0.0% | 43—479% | 1.5r−0.2*−38.5%11.7% | 0r0*−100%0.0% | 20r22*+468%182% | 0−100%0.0% | 2.5r3.0*—30.5% | 5.8*—79.5% | 3.6*—48.9% | 3.1—48.6% | 0*—0.0% | |
| Cash from financing activities | 43+27.7%92.1% | 0.1*+63.4%1.0% | −0.1*−100%−0.5% | 42+338%476% | 0.3*−90.7%2.1% | 0.1*−98.6%0.7% | 21*−20.3%185% | 9.7+210%106% | 3.0*+6863%36.2% | 5.8*—79.2% | 26*—353% | 3.1—48.4% | 0.0*—0.8% | |
| Change in cash | 18+58.1%38.8% | −5.2*—−40.6% | −10*−176%−90.0% | 36+699%402% | −2.2*—−17.0% | −3.8*—−32.9% | 13*+7.8%120% | 4.5—48.8% | −2.8*—−33.4% | −5.2*—−70.7% | 13*—170% | −7.8—−121% | −9.5*—−166% | |
| Report | Worked out | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-K/A | |
* Worked out from reported figures: a quarter the company states only within a year-to-date figure (cash flows are reported that way), or the fourth quarter as the fiscal year minus the first nine months.
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.
Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative
Executive pay at TriSalus Life Sciences, Inc.#
From the pay-versus-performance table of the company's proxy statement. “Actually paid” marks share awards to their current value.
| Fiscal year | CEO total pay | Actually paid | Other executives, average | $100 invested |
|---|---|---|---|---|
| 2025Mary Szela | $4.8 M | $6.9 M | $2.5 M | $83 |
| 2024Mary T. Szela | $4.1 M | $1.5 M | $1.8 M | $59 |
Source: SEC proxy statement (Form DEF 14A) · as of Dec 31, 2025
Events at TriSalus Life Sciences, Inc.#
What the company reported to the SEC within four business days (Form 8-K), newest first.
No warning signs in the last three years: no bankruptcy, delisting notice, withdrawn financial statements, auditor change, cybersecurity incident, debt called early or impairment was reported.
Directors and officers 10 · Material agreement 2 · New debt 1 · Unregistered share sale 2 · Shareholder rights changed 1 · Bylaws or fiscal year changed 1 · Shareholder vote 3 · Results announced 12
| Filed | What happened | Filing |
|---|---|---|
| Results announced | 8-K | |
| Results announced | 8-K | |
| Shareholder vote | 8-K | |
| Results announced | 8-K | |
| Directors and officers | 8-K | |
| Directors and officers | 8-K | |
| Results announced | 8-K | |
| Material agreement | 8-K | |
| Directors and officers | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Directors and officers | 8-K | |
| Directors and officers | 8-K | |
| Results announced | 8-K | |
| Shareholder rights changedBylaws or fiscal year changedShareholder vote | 8-K | |
| Shareholder vote | 8-K | |
| Directors and officers | 8-K | |
| Results announced | 8-K | |
| Material agreementUnregistered share saleResults announced | 8-K | |
| Directors and officers | 8-K | |
| Directors and officers | 8-K | |
| Results announced | 8-K | |
| Directors and officers | 8-K | |
| New debtUnregistered share sale | 8-K | |
| Results announced | 8-K | |
| Directors and officers | 8-K | |
| Results announced | 8-K |
Source: SEC EDGAR, Form 8-K item numbers · as of Nov 10, 2026
Acquisitions and funding#
Private share sales · funding history
Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.
Lobbying by TriSalus Life Sciences, Inc.#
$360 K spent on lobbying the US Congress and federal agencies in 2025, most often on medicare/medicaid.
- Medicare/Medicaid4 reports
Lobbying firms hired in 2025
Capitol Hill Consulting Group $360 K
| Year | Spending | Own lobbyists | Reports |
|---|---|---|---|
| 2026 (so far) | $270 K | — | 3 |
| 2025 | $360 K | — | 4 |
| 2024 | $390 K | — | 7 |
| 2023 | $360 K | — | 11 |
| 2022 | $240 K | — | 9 |
| 2021 | $0 | — | 5 |
| 2020 | $40 K | — | 4 |
| 2019 | $120 K | — | 4 |
| 2018 | $180 K | — | 2 |
Source: Lobbying Disclosure Act reports (Form LD-2). Filed as “TriSalus Life Sciences”. Reports round to the nearest $10,000, and one of less than $5,000 counts as zero
How TriSalus Life Sciences, Inc. compares in Healthcare
- Market cap$234 M · higher than 36% of 2,013
- Revenue$45 M · higher than 33% of 1,795
- Net margin-56.6% · higher than 22% of 1,485
- Revenue growth53.4% · higher than 83% of 1,003
- Price / sales5.0× · lower than 39% of 1,071
- FCF yield-8.1% · higher than 44% of 835
Peer comparison · Healthcare
| Company | Market cap | P/E | Net margin | Rev. growth |
|---|---|---|---|---|
| TriSalus Life Sciences, Inc.🇺🇸 | $234 M | — | -56.6% | +53.4% |
| Eli Lilly and Company🇺🇸 | $1.20 T | 43.4× | 31.9% | +44.7% |
| Johnson & Johnson🇺🇸 | $652.5 B | 40.5× | 16.2% | +6.0% |
| AbbVie Inc.🇺🇸 | $514.0 B | 49.7× | 15.7% | +8.6% |
| Roche Holding AG🇨🇭 | $370.3 B | 29.1× | 19.0% | — |
| UnitedHealth Group Incorporated🇺🇸 | $367.7 B | 23.1× | 3.5% | +11.8% |
| Merck & Co., Inc.🇺🇸 | $359.8 B | 146.7× | 3.6% | +1.3% |
| Novartis AG🇨🇭 | $286.8 B | 20.5× | 24.7% | — |
| Thermo Fisher Scientific Inc.🇺🇸 | $253.8 B | 35.9× | 14.9% | +3.9% |
P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.
Questions, comparisons and similar companies#
Questions people ask
Compare head to head
Similar companies by size and industry
Sources and freshness
- Market cap:
- Oct 28, 2026
- Annual results:
- For year ending December-2025
- Balance sheet:
- As of December-2025
- Employees:
- As of December 31, 2025
- Profile updated:
- Nov 20, 2026
Figures from Market data, SEC filing, value.today research, SEC annual report; financial statements from SEC filings.
How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.
Work at TriSalus Life Sciences, Inc.? Verify and update this profile — free
Show TriSalus Life Sciences, Inc.'s ranking or a chart on your website Get the badge
The badge updates itself as the ranking changes.